India is preparing to introduce its first quadrivalent HPV vaccination, created locally to prevent cervical cancer, on Thursday. The Serum Institute of India and the Department of Biotechnology collaborated on its development. HPV vaccinations, required to prevent cervical cancer, had previously been purchased from international producers for between Rs 2,000 and Rs 3,500 per
dosage.
New Delhi: The first locally manufactured quadrivalent Human Papillomavirus (HPV) vaccine for cervical cancer prevention is slated to be on sale in India on Thursday. It was produced by the Department of Biotechnology and the Serum Institute of India (SII) (DBT).
HPV vaccinations, which are required to prevent cervical cancer, were purchased from international manufacturers for between Rs 2,000 and Rs 3,500 per dosage. According to sources, the indigenous vaccination will likely be far less expensive and, therefore, more accessible.
Depending on the patient’s age at the initial immunization, the HPV vaccine is administered in two to three doses. Last month, the Serum Institute of India (SII) received market authorization from the Drugs Controller General of India (DCGI) to produce the locally designed cervical cancer vaccine.
Nearly 1.23 lakh cases and 67,000 fatalities from cervical cancer occur in India yearly, making up about a quarter of the disease’s global burden. According to sources, the availability of a cheap vaccination to stop the disease could help save countless lives.
A sexually transmitted infection called the human papillomavirus (HPV) is linked to the majority of cases of cervical cancer. According to the Mayo Clinic, widespread HPV vaccination could lessen the prevalence of cervical cancer and other HPV-related cancers.
Most occurrences of cervical cancer are linked to different HPV strains, which are transmitted through sexual contact. According to the Mayo Clinic, an HPV vaccination can prevent cervical cancer if given to girls and women before exposure to the virus. According to a recent report in the Indian Journal of Gynecologic Oncology, immunization against high-risk HPV strains is a secure and reliable method of preventing cervical cancer in its early stages.
